Skip to main content

Marc Miravitlles Fernández

I’m a specialist in Respiratory Medicine trained at Vall d’Hebron Hospital in Barcelona. My focus is on clinical research in chronic obstructive pulmonary disease (COPD) and alpha-1 antitrypsin deficiency (AATD) with the objective to find a cure and improve the quality of life of patients suffering these chronic respiratory diseases.

Institutions of which they are part

Main researcher
Pneumology
Vall Hebron Institut de Recerca
Doctor
Pneumology
General Hospital

Marc Miravitlles Fernández

Institutions of which they are part

Main researcher
Pneumology
Vall Hebron Institut de Recerca
Doctor
Pneumology
General Hospital

I’m a specialist in Respiratory Medicine trained at Vall d’Hebron Hospital in Barcelona. My focus is on clinical research in chronic obstructive pulmonary disease (COPD) and alpha-1 antitrypsin deficiency (AATD) with the objective to find a cure and improve the quality of life of patients suffering these chronic respiratory diseases.

I’m a Pulmonologist and Senior Researcher at the Vall d’Hebron University Hospital and the Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain.
I obtained my MD at the Universitat de Barcelona, Barcelona, Spain in 1986 and my PhD at the Universitat Autònoma de Bacelona in 1997. I trained as specialist in Respiratory Medicine at Vall d'Hebron Hospital. My primary research interests include chronic obstructive pulmonary disease (COPD), alpha-1-antitrypsin deficiency (AAT), lung defence mechanisms and respiratory infections. I served as Secretary General of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) from 1999 to 2003 and I was responsible for International Relationships of SEPAR from 2006 until 2012. I was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) from 2008 to 2011 and I was the Guidelines Director of the ERS from 2015 to 2018.
I have acted as a consultant and/or chair or author for the development of different international guidelines of COPD, including the American Thoracic Society (ATS)/ERS task force on outcomes in COPD, the ERS/ATS guidelines on diagnostic and treatment of exacerbations of COPD and the ERS statement on management of alpha-1 antitrypsin deficiency. I am also a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD (2009 to present) and coordinator of the Spanish National Guidelines for COPD (GesEPOC from 2012). I am the director of the reference center for diagnosis and treatment of AATD in the Hospital Vall d’Hebron and I am author of 498 publications listed in PubMed and a h-index of 73 (May 2020)

Projects

Grup de Recerca en Pneumologia

IP: Jaume Ferrer Sancho
Collaborators: Sergi Martí Beltran, Marta Vicenta Arjona Perís, Christian Eduardo Romero Mesones, Maria Angeles Jiménez Fuentes, Mª Jose Jurado Luque, Marc Miravitlles Fernández, Ana Villar Gomez, Antonio Álvarez Fernandez, Victor Monforte Torres, Odile Romero Santo-Tomas, Miriam Barrecheguren Fernández, David Clofent Alarcón, Carles Bravo Masgoret, Mario Culebras Amigo, Fco. Javier Muñoz Gall, Gabriel Sampol Rubio, Maria Antonia Ramon Belmonte, Mercedes Pallero Castillo, Mª Jesús Cruz Carmona, Cristina Berastegui Garcia, Almudena Felipe Montiel, Gerard Orriols Torras, Victoria Ruiz De Miguel, Meritxell Boada Perez, David Espejo Castellanos, Manuel López Meseguer, David Soler Segovia, Susana Gómez Olles, Cristina Esquinas López, Berta Saez Gimenez, Grup de Recerca en Pneumologia, Iñigo Ojanguren Arranz, Eva Polverino , Alexa Gabriela Nuñez Dubon, Letizia Traversi
Funding agency: AGAUR no fer servir-correcte 4301-37
Funding: 0.01
Reference: 2021 SGR 00788
Duration: 01/01/2022 - 31/12/2024

Caracterización y factores de riesgo de las SEcuelas PULmonares de los pacientes que superan una neumonía por COVID-19 (PULSE-COVID).

IP: Fco. Javier Muñoz Gall
Collaborators: Maria Angeles Jiménez Fuentes, Marc Miravitlles Fernández, David Clofent Alarcón, David Soler Segovia
Funding agency: Instituto de Salud Carlos III
Funding: 135520
Reference: PI21/01046
Duration: 01/01/2022 - 31/12/2024

Pendent

IP: Marc Miravitlles Fernández
Collaborators: Alexa Gabriela Nuñez Dubon
Funding agency: Instituto de Salud Carlos III
Funding: 53732
Reference: CM19/00215
Duration: 01/01/2020 - 22/04/2022

Estudio de patogénesis de la enfermedad oulmonar obstructiva crónica mediante técnicas de biología molecular y computacional: Una opción para nuevas modalidades de tratamiento.

IP: Marc Miravitlles Fernández
Collaborators: Miriam Barrecheguren Fernández, Cristina Esquinas López
Funding agency: Instituto de Salud Carlos III
Funding: 147620
Reference: PI18/01376
Duration: 01/01/2019 - 30/06/2023

Related news

Vall d'Hebron participated in the study in which more than half of the patients who received treatment with bacteriophages experienced significant improvements

La recerca és fonamental per contrarestar els efectes de la pol·lució, que segons l’AEMPS, va ser la causa de més de 300.000 morts prematures a la UE el 2020.

Pulmonary hypertension is a risk factor for patients who need surgery and, therefore, defining strategies for its management is important to allow a favorable clinical evolution.

Related professionals

Laia Martinez Mitjana

Laia Martinez Mitjana

Research technician
Rheumatology
Read more
David Espejo Castellanos

David Espejo Castellanos

Predoctoral researcher
Pneumology
Read more
Alex Escarrà Pont

Alex Escarrà Pont

Research technician
Pharmacokinetic Nanoparticles
Read more
Núria Martínez Gil

Núria Martínez Gil

Postdoctoral researcher
Genetics Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.